Clay Siegall is the founder and chief executive officer of Seattle Genetics, a company that develops target therapy drugs for diseases that have caused numerous deaths in the recent years. Clay Siegall was interested in medicine, the power of technology as well as the desire to overcome diseases for long. He had a great passion for restoring people’s health.
His interest in cancer treatment mainly grew while he was a student of zoology at the University of Maryland. One of his family members was diagnosed with cancer. The treatment did not augur well with the patient. It was brutal. The patient developed anemia and was on the verge of dying, not from cancer but the chemotherapy treatment. Siegall came to learn of other ways of treatment such as amputation and radical surgery. That is how the idea of starting up Seattle Genetic firm was conceived.
The able leadership of Clay Siegall has seen Seattle Genetics become the pinnacle of the therapy industry that is focused on. It recently came up with the first antibody drugs approved by the FDA and have been widely adopted. Seattle Genetics has also developed a line of more than 20 drugs. Besides this, the leadership of Clay Siegall has seen the company collaborating with renowned drug manufacturers such as Bayer, Pfizer, and Genentech among other.
Seattle Genetics started small with a few researchers. It has since grown to become a player in the cancer research. Certainly, the company is not stopping at the current achievements. Clay Siegall intends to take the company even higher. Seattle Genetics is among industry leaders and can play a part in the 21st-century drug development industry. It is the sincere belief of Clay Siegall that the systemic chemotherapies will soon be a thing of the past and that more tolerable and efficient targeted drugs will soon outdo the old time therapies.
Before starting his own company, Clay Siegall worked at Bristol-Myers Squibb Pharmaceutical Research Institute for five years. He had also been part of the National Cancer Institute as well as the National Institute of health. Clay received his Ph.D. in Genetics from George Washington University.